VX1 Stock Overview
A biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for VX1 from our risk checks.
Vertex Pharmaceuticals Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$424.55 |
| 52 Week High | US$487.00 |
| 52 Week Low | US$315.10 |
| Beta | 0.39 |
| 11 Month Change | -4.06% |
| 3 Month Change | -2.46% |
| 1 Year Change | 30.03% |
| 33 Year Change | 154.59% |
| 5 Year Change | 112.17% |
| Change since IPO | 1,418.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| VX1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -9.4% | 0.8% | -0.4% |
| 1Y | 30.0% | -16.7% | 7.1% |
Return vs Industry: VX1 exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: VX1 exceeded the German Market which returned 7.8% over the past year.
Price Volatility
| VX1 volatility | |
|---|---|
| VX1 Average Weekly Movement | 4.2% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: VX1 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: VX1's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 5,400 | Reshma Kewalramani | www.vrtx.com |
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company’s pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial.
Vertex Pharmaceuticals Incorporated Fundamentals Summary
| VX1 fundamental statistics | |
|---|---|
| Market cap | €109.47b |
| Earnings (TTM) | -€455.23m |
| Revenue (TTM) | €10.08b |
10.9x
P/S Ratio-242.2x
P/E RatioIs VX1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VX1 income statement (TTM) | |
|---|---|
| Revenue | US$10.63b |
| Cost of Revenue | US$4.93b |
| Gross Profit | US$5.69b |
| Other Expenses | US$6.17b |
| Earnings | -US$479.80m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.86 |
| Gross Margin | 53.59% |
| Net Profit Margin | -4.52% |
| Debt/Equity Ratio | 0% |
How did VX1 perform over the long term?
See historical performance and comparison